Valneva SE

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 Nov 2023 01:30:00 By Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 Nov 2023 02:30:00 By Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 Oct 2023 12:15:00 By Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 Oct 2023 11:45:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 Oct 2023 02:30:00 By Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 Sep 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 Sep 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 Sep 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 Sep 2023 02:30:00 By Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 Aug 2023 13:00:00 By Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

28 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Extension of Existing Loan Agreement

17 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

14 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - July 31, 2023

03 Aug 2023 02:30:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: June 30, 2023

05 Jul 2023 02:30:00 By Nasdaq GlobeNewswire

Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors

22 Jun 2023 01:00:00 By Nasdaq GlobeNewswire